| Id: | acc3478 |
| Group: | 2sens |
| Protein: | ERK1 |
| Gene Symbol: | Mapk3 |
| Protein Id: | Q63844 |
| Protein Name: | MK03_MOUSE |
| PTM: | phosphorylation |
| Site: | Thr202 |
| Site Sequence: | DPEHDHTGFLTEYVATRWYRA |
| Disease Category: | Immune system diseases |
| Disease: | Inflammatory |
| Disease Subtype: | Inflammatory Bowel Disease |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | decitabine |
| Drug Info: | Decitabine is a hypomethylating agent used in the treatment of myelodysplastic syndromes and other hematological malignancies. |
| Effect: | modulate |
| Effect Info: | "Decitabine can increase the levels of zonular occludens-1 and occludin, inhibit the phosphorylation of ERK1/2, JNK and p38, and relieve DSS-induced colonic barrier dysfunction, weight loss, mucus and bloody stools in mice." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 32468024 |
| Sentence Index: | 32468024_8-9 |
| Sentence: | "Furthermore, decitabine increased the levels of zonular occludens-1 and occludin, and inhibited the phosphorylation of ERK1/2, JNK and p38. In conclusion, the present study suggested that decitabine could alleviate DSS-induced impaired colon barrier and the weight loss, mucus and bloody stools in mice by releasing the inhibitory factor IL-10, reducing the pro-inflammatory factor IL-17, activating CD4+ Foxp3+ T cells and inhibiting the activation of the MAPK pathway." |
Sequence & Structure:
MAAAAAAPGGGGGEPRGTAGVVPVVPGEVEVVKGQPFDVGPRYTQLQYIGEGAYGMVSSAYDHVRKTRVAIKKISPFEHQTYCQRTLREIQILLRFRHENVIGIRDILRAPTLEAMRDVYIVQDLMETDLYKLLKSQQLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLINTTCDLKICDFGLARIADPEHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINMKARNYLQSLPSKTKVAWAKLFPKSDSKALDLLDRMLTFNPNKRITVEEALAHPYLEQYYDPTDEPVAEEPFTFDMELDDLPKERLKELIFQETARFQPGAPEGP
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| T | 203 | U | Squamous cell carcinoma | Phosphorylation | 19934324 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
